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ABSTRACT 
Background and aim. Vitamin D exerts its biochemical function on 
skeletal muscle through vitamin D receptors (VDR). Vitamin D deficiency 
is highly prevalent in the general population especially in the elderly. It is 
postulated that lower vitamin D levels lead to reduced expression of VDR 
in skeletal muscles. This then may lead to reduced muscle strength, 
function and ultimately falls in the elderly. The aim of this study was to 
examine the relationship between human ageing, circulating vitamin D 
levels and VDR expression in human skeletal muscle.  
 
Methods. Twenty six participants were recruited to the study; 8 young 
participants, 8 older participants who were vitamin D sufficient (25-OH-D3 
QPRO/DQGolder participants who were vitamin D insufficient 
(<50nmol/L). Blood samples were obtained for the determination of 
serum 25-OH-D3, calcium and parathyroid hormone (the latter only for 
older participants); and a muscle biopsy of their thigh (vastus lateralis 
muscle) was performed using a Magnum biopsy system. Real time 
quantitative PCR was used to measure the expression of VDR and some of 
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its target genes P\RVWDWLQ6LU33$5ĮDQG33$5įLQKXPDQVNHOHWDO
muscle. VDR protein content was measured using Western Blotting.  
 
Main findings. Hypovitaminosis D was highly prevalent in the young 
participants recruited into the study, but it was not statistically different 
from the older participants who were vitamin D insufficient. Higher 
expression of VDR and PPARį mRNA was observed in both older sufficient 
and insufficient groups when compared with the younger group (p=0.01). 
There was also higher sirt1 mRNA expression (p=0.00) and a tendency 
WRZDUGVKLJKHU33$5ĮH[SUHVVLRQS LQWKHROGHUVXIILFLHQWJURXS
when compared to the younger group. There was no difference in skeletal 
muscle content of the myostatin gene between groups. When the young 
group was compared with the older insufficient group, levels of VDR 
P51$DQG33$5įwere still higher in the older group. Gene expression did 
not appear to be strongly influenced by circulating 25-OH-D3 levels in any 
of the respective participant groups. Western blotting was unsuccessful in 
detecting VDR protein content despite the use of 2 different VDR 
antibodies.  Tissue availability and time constraints precluded further 
work to be done.  
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Conclusion. Similar VDR mRNA and target gene expression levels were 
expressed in both older sufficient and insufficient groups; and higher VDR 
mRNA was seen in the older insufficient group compared with the younger 
participants. This suggests that the ageing process may be influencing the 
expression of these genes. Circulating 25-OH-D3 levels did not appear to 
affect gene expression.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 Background and brief history of vitamin D 
Vitamins are a heterogenous group of organic substances obtained from 
dietary intake. They are only needed in small quantities for the 
maintenance of normal cell and organ function. Vitamin D is not in its 
truest sense a vitamin but a secosteroid as it is predominantly obtained 
intrinsically by the effect of ultraviolet (UV) radiation on previtamin D 
compounds in the skin and subsequent hydroxylation in the liver and 
kidneys [Basu 1996]. It was described as a vitamin during the early 
developments where deficiency of certain micronutrients in diet led to 
pathological conditions such as xerophthalmia (vitamin A deficiency), beri 
beri (vitamin B1 deficiency) and scurvy (vitamin C deficiency). Sir Edward 
Mellanby in the 1920s discovered that those suffering with rickets, a 
condition characterized by soft and weak bones, were cured when cod 
liver oil was given to them. Professor Elmer McCollum at John Hopkins 
University subsequently noted that after eliminating vitamin A from cod 
liver oil, its curative effects for rickets remained leading to the discovery 
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of a new micronutrient, which was called vitamin D. At the same time, 
researchers in Europe and Professor Harry Steenbock at the University of 
Wisconsin started to discover the relationship between ultraviolet light 
and adequate calcium homeostasis. However, it was not till the 1930s 
that the structure of vitamin D was isolated which perpetuated our 
understanding and our ongoing research of its biochemical properties and 
function [DeLuca 2014].   
 
1.2 Structure, metabolism and regulation of vitamin D 
Two forms of vitamin D, ergocalciferol (vitamin D2) and cholecalciferol 
(vitamin D3) have most clinical relevance. Both forms of vitamin D can be 
obtained from dietary intake, such as oily fish, eggs and milk, and they 
are absorbed by the small intestine. However, predominantly human 
vitamin D is endogenously synthesized by the action of UV light to 
cholecalciferol or vitamin D3 (Figure 1).  UV light (wavelength 285-
315nm) action on 7-dehydrocholesterol, a cholesterol based precursor in 
the skin leads to the formation of previtamin D3. Previtamin D3 remains in 
a thermal equilibrium with vitamin D3 and its conversion is affected by the 
VNLQ¶VSURSHUWLHVHWKQLFLW\DJHDQGWKe environment (UV exposure, 
geographical location). Both dietary and endogenous vitamin D undergoes 
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25-hydroxylation in the liver where a hydroxyl group is added at the 
carbon-25 atom to yield 25-hydroxycholecalciferol (or 25-hydroxyvitamin 
D, or 25-OH-D3). This is the main circulating form of vitamin D and at 
normal plasma concentration of this metabolite, only small amounts of it 
are released into the systemic circulation to affect its target tissues. 
Hence, 25-OH-D3 is the most routinely measured form of vitamin D in 
clinical practice. Next, there is further hydroxylation in the kidney which is 
DUDWHOLPLWLQJVWHSLQWKHV\QWKHVLVRIYLWDPLQ'¶VDFWLYHPHWDEROLWH7KH
HQ]\PHĮ-hydroxylase mediates the production of 1,25-
dihydroxycholecalciferol (or 1,25-dihydroxyvitamin D, or 1,25-(OH)2-D3), 
the active hormone calcitriol. Multiple factors influence the regulation of 
the hydroxylation that happens in the kidney. This includes calcium, 
parathyroid hormone (PTH), calcitonin, growth hormone, insulin like 
growth factor-1 and fibroblast growth factor 23. 1,25-(OH)2- D3 itself 
suppresses its hydroxylation by Į-hydroxylase ensuring optimal 
homeostasis within the body [Girgis 2013].  
 
Another important enzyme in the metabolism of vitamin D is 24-
hydroxylase which is highly present in the kidneys. It limits the amount of 
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1,25-(OH)2-D3 in target tissues by metabolising it into inactive forms 
(1,24,25-(OH)2-D3 or 24,25-OH-D3).  
 
 
 
Figure 1 Vitamin D metabolism (adopted from Dirks-Naylor 2011). Metabolism 
of vitamin D from dietary intake and the skin precursor, 7-dehydrocholesterol by 
UV radiation to pre-vitamin D, and its subsequent hydroxylation in the liver and 
kidney to its active form.   
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Vitamin D regulates and is also largely regulated by calcium homeostasis. 
Low plasma calcium concentration activates calcium sensing receptors in 
the PTH gland increasing PTH release. This increases production of the 
active form of vitamin D, 1,25-(OH)2- D3 via the metabolic pathway 
described above. This active form of vitamin D3 acts on osteoblasts by 
inducing the release of the receptor activator of nuclear factor (NF)-Ŧ%
(RANKL) which in turn promotes osteoclastogenesis which will increases 
bone resorption. It also increases intestinal absorption of calcium by 
promoting its dietary absorption; and the activity of 1-hydroxylase in the 
kidneys to produce more active vitamin D. The 1,25-(OH)2- D3 
synthesised and the rising calcium level will have a negative feedback on 
the expression of PTH which will ultimately reduce efforts to increase 
levels of calcium [Geissler 2005].   
 
1.3 Function of vitamin D 
9LWDPLQ'¶VPDLQUROHLVin maintaining calcium (and phosphate) 
homeostasis by its action on the bone, intestine and kidneys. Vitamin D 
has been shown to strengthen bones. In animal models, incubation of 
bones with serum of animals given vitamin D has shown deposition of 
calcium and phosphate and strengthening of rachitic bones [DeLuca 
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2014]. Besides that, vitamin D has also been shown to mobilise calcium 
out of bones to maintain calcium homeostasis. It has also shown to be 
responsible for the absorption of calcium and phosphate from the 
intestine [Nicolayson 1953]. 
 
Vitamin D exerts its effects via genomic and non-genomic pathways. It 
exerts its genomic effects by regulating gene expression and modulation; 
and its non-genomic effects through muscle function via calcium, 
phosphate, insulin and glucose regulation.  
 
Our initial understanding of the function of vitamin D started around its 
skeletal effects. From its initial discovery as an antirachitic element, it has 
been noted that a deficiency in vitamin D leads to weak, fragile and 
impaired growth of bones. In adults, a deficiency in vitamin D leads to 
osteomalacia where it is characterised by skeletal pain, muscle weakness 
and osteoporosis. A lack of vitamin D can also affect muscles and bones 
without the features of osteomalacia [Gelrup 2000]. It impairs function of 
osteoclasts and osteoblasts leading to a decline in bone density making 
bones susceptible to low trauma fractures.  
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In recent years, our understanding of vitamin D and its function have 
extended beyond its role in bone integrity and calcium homeostasis. 
Current literature has drawn links between vitamin D and falls [Bischoff 
Ferrari 2009], reduced muscle strength [Glerup 2000], cancer [Garland 
2006, Deeb 2007], diabetes mellitus [Hypponen 2001, Pittas 2007], 
cardiovascular disease [Wang 2008], and the immune system [Cantorna 
2004, Kamen 2010]. This is because vitamin D receptors (VDR) have 
been located in bone, gastrointestinal tract, liver, pancreas, kidney, heart, 
skeletal muscles, immune system, nervous system, and other endocrine 
organs [Coombs 1998]. This discovery adds weight to the extraskeletal 
effects of vitamin D and has fuelled research into better understanding of 
the function of vitamin D and whether either vitamin D levels or 
supplementation of vitamin D has beneficial clinical implications beyond 
bone health.  
 
1.4 Vitamin D and vitamin D receptors 
Vitamin D receptors (VDR) was first discovered in 1974 by Brumbaugh 
and Haussler in animal intestines [Brumbaugh 1974]. Since then, VDR 
has been detected in other tissue such as the kidneys, bone and skeletal 
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muscle. The integral importance of VDR in musculoskeletal function has 
been well demonstrated in VDR knock-out mice where these mice exhibit 
traits consistent with rickets. Some of these similar features were also 
noted in these mice and patients with vitamin D dependent rickets type 2 
where the defect is within the VDR itself [Kato 2000]. VDR knock-out 
mice were also noted to have a lack of muscle development [Montero 
2005]. Using immunohistochemical methods, Bischoff et al were able to 
demonstrate the presence of VDR in human skeletal muscle. They were 
able to demonstrate strong intranuclear immunostaining of VDR in gluteal 
and tranversospinalis muscles using monoclonal antibody 9A7 [Bischoff 
2001]. Circulating 1,25-(OH)2-D3, bound to vitamin D binding protein is 
transferred to its target tissue where it exerts its biological effects 
through its binding with vitamin D receptors (VDR). This vitamin D-VDR 
ligand then activates target gene expression at the transcriptional level 
[Kato 2000]. Hence, it is the internal synthesis of vitamin D by the action 
of UV radiation on its precursor in the skin; the synthesis of its active 
metabolite away from its origin; its action depending on receptor 
proteins; and its regulation by a feedback mechanism, which makes 
vitamin D more akin to the action of a hormone [Basu 1996].  
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As described earlier, the genomic pathway from which 1,25-(OH)2-D3 
works involve binding with liganded nuclear VDR. Nuclear VDR forms 
homodimers, or heterodimers with retinoid X-receptors (RXR). RXRs are 
nuclear receptors that are activated by 9-cis retinoic acid, a metabolically 
active form of vitamin A. The VDR homodimer or heterodimer then binds 
to specific enhance elements, called vitamin D response elements (VDRE) 
in response to activation by the circulating 1,25-(OH)2-D3. It is this 
binding mechanism that leads to its ability to affect the cellular genomic 
pathway. Co-activators that interact with VDR have also been recently 
shown to be essential for the transcription process but their precise 
mechanism is yet to be fully understood [Kato 2000, Haussler 2008, 
Girgis 2013].  The vitamin D dependent modulation of mRNA 
subsequently leads to de novo protein synthesis which affects target 
genes that are associated with cell differentiation and proliferation, 
energy metabolism, hormonal signalling, mineral homeostasis, 
oncogenes, and vitamin D metabolism (Figure 2). The first gene product 
or protein identified was calcium binding protein (CaBP). Different forms 
of CaBP have later on been described and these are called calbindins 
[Combs 1998, Annweiler 2010].  
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One other protein that has recently being identified as a target of VDR 
expression is Sirtuin1 (sirt1). Sirt1 is a NAD dependent protein 
deacetylase that has a complex metabolic function which includes gene 
splicing, DNA repair and metabolic regulation [Price 2012]. It is found in a 
number of tissues, which include liver, brain, adipose tissue and skeletal 
muscles [Satoh 2013]. Price et al demonstrated in mice models that sirt1 
overexpression had a similar effect with treatment with resveratrol 
(2,3,40-trihydroxystilbene), a naturally occurring substance found in 
certain plants that is associated with delaying the ageing process [Price 
2012]. They were also able to demonstrate that resveratrol treated mice 
had more type 2 muscle fibres and better mitochondrial function; and that 
resveratrol function was dependent on sirt1 expression. Satoh et al has 
also shown that overexpressed sirt1 mice were shown to have significant 
life span and delay in the ageing process compared to control mice [Satoh 
2013]. They demonstrated that brain specific sirt1 overexpressing mice 
had a slower rate of ageing, physiological decline and more youthful 
skeletal muscle structure, with better organisation of sarcomeres and less 
abnormal mitochondria, compared to control mice. Mitochondrial 
dysfunction is recognised to be pathognomonic of the ageing process and 
development of disease, and the findings described here highlights the 
crucial role sirt1 plays in the ageing process [Erol 2007]. Sirt1 is also 
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recognised in its role of promoting oncogenesis and also as a tumour 
suppressor gene, thus, raising its role in cancer on top of healthy ageing. 
An et al were able to show a link between vitamin D signalling via VDR 
and Sirt1 through its regulation of FoxO protein, a group of transcription 
factors that regulate cell proliferation, growth and longevity. One of the 
ways FoxO is regulated is by acetylation which can be reversed by sirt1. 
This reduces DNA binding and enhances phosphorylation and inactivation. 
VDR is associated directly with sirt1 in a partially hormone-dependent 
manner, as assessed by GST pulldown assay and coimmunoprecipitation. 
Vitamin D also enhances the recruitment of sirt1 to FoxO3a, as shown 
during coimmunoprecipitation of Sirt1 with an anti-FoxO3a antibody [An 
2010].  
 
Another target gene for vitamin D function are the peroxisome 
proliferator-activated receptors (PPARs). PPARs are proteins that function 
as transcription factors to regulate the expression of genes. It has a fairly 
extensive role that includes cell proliferation, differentiation, glucose 
homeostasis, insulin sensitivity, lipid metabolism, bone formation and 
tissue remodelling [Erol 2007]. PPARs are noted to be involved in the 
inflammatory process seen in ageing, where it suppresses the expression 
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of inflammatory genes, cytokines and acute phase proteins [Chung 2008]. 
3 isoforms exist which are alpha (ĮGHOWDįDQGJDPPDǄ33$5ĮLV
expressed in tissues with high fatty acid catabolism such as kidney, heart 
DQGVNHOHWDOPXVFOHV33$5įLQVNLQEUDLQDGLSRVHWLVVXHNLGQH\KHDUW
DQGGLJHVWLYHWUDFWDQG33$5ǄLQDGLSRVHWLVVXHV>6HUWznig 2009]. PPARs 
are able to form heterodimers with RXR, similar to VDR to specific DNA 
regions of target genes. This heterodimer of PPAR/VDR-RXR bind to their 
specific response elements, have interconnected pathways that regulate 
the target genes and its respective transcription factor mRNA levels 
[Matsuda 2013]. This crosstalk link between VDR and PPAR means that 
ERWKLVDEOHWRLQIOXHQFHHDFKRWKHU¶VSDWKZD\DQGWKDW33$5LVD
coactivator in the way vitamin D-VDR exerts its genomic effects.  
Certainly this link has been demonstrated in studies looking at breast and 
skin cancer [Sertznig 2009, Alimirah 2012]. 
 
1,25-(OH)2-D3 leads to uptake of calcium into muscles and this is inhibited 
when VDR pathways are blocked. This points towards a direct non-
genomic role for VDR in muscle function [Girgis 2013]. The non-genomic 
effects of vitamin D arise from a series of complex intracellular signal 
transduction pathways after binding to a nonnuclear receptor, membrane 
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bound VDR [Montero 2005; Girgis 2013]. These non-genomic effects have 
been the subject of much research interest, especially its effect on 
skeletal muscle due to the high prevalence of muscle weakness, falls and 
subsequent fracture in a progressively ageing population. 
 
 
Figure 2 Molecular mechanism of vitamin D action through VDR mediated gene 
expression (adapted from Kato 2000). It shows 1,25-(OH)2-D3 bound to VDR-
RXR heterodimers to affect the target gene, its promotion of mRNA and 
subsequently its action in its target tissues.  
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1.5 Skeletal muscle and vitamin D 
Skeletal muscles are made of grouped fascicles which itself is made up of 
individual muscle fibres. When muscle contracts, the sarcomeres and 
myofibrils which make up the individual muscle fibres decreases and 
shortens. Despite this, the muscle length itself does not change. This is 
H[SODLQHGE\+X[OH\¶VVOLGLQJILODPHQWWKHRU\RIFRQWUDFWLRQ,WVWDWHVWKDW
during contraction, the thick and thin filaments of the muscle slide past 
each other and overlaps. This contraction is modulated by an electrical 
event, an action potential which causes a transient rise in intracellular 
calcium levels [Marieb 1998]. The action potential and its muscle 
contraction is regulated by oxidative and glycolytic metabolic pathways 
[Girgis 2013]. Macroscopically, muscle contraction is dependent on size, 
fibre composition and individual fibre functional capacity. Skeletal muscles 
are divided by histochemical staining that determine the pH lability of 
myofibril ATPase activity to myosin heavy chain (MHC) type 1 (slow 
activity) and type 2 (fast activity). Besides generating force and 
contraction, skeletal muscles are a highly metabolic organ that responds 
to hormones and factors, such as exercise. Calcium is noted to be an 
integral component in muscle contraction.  
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The relationship between vitamin D and skeletal muscle has been well 
observed in those with osteomalacia, where vitamin D deficiency leads to 
muscle weakness. However, those deficient may also exhibit muscle 
weakness without any of the features of osteomalacia [Glerup 2000]. 
Other patterns observed include proximal weakness and a waddling gait 
[Ceglia 2008]. Musculoskeletal pain has also been reported in those 
lacking in vitamin D [Montero 2005]. Vitamin D supplementation in those 
with deficiency also appears to improve muscle strength, postural stability 
and gait speed [Dhesi 2002, Bischoff-Ferrari 2004, Pfeifer 2009]. 
Research has also shown the benefits of vitamin D in preventing falls in 
those deficient in community dwellers and those in long term institution 
which support the role vitamin D plays in maintaining muscle strength 
and balance [Cameron 2012].  
 
Those with vitamin D deficiency have been predominantly shown to have 
atrophy of type 2 fibres on muscle biopsy. It is the fast acting type 2 
fibres that are called to action in the event of a fall to attempt to maintain 
posture and balance [Ceglia 2008]. Supplementation with vitamin D has 
been shown to increase the number and size of these fibres resulting in 
an increase in muscle strength [Sato 2005] which may explain the 
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improvement seen in clinical practice. Central to this is the very presence 
of VDR in skeletal muscle in regulating calcium homeostasis and muscle 
contraction. This VDR genomic pathway has been described to affect 
calcium uptake and transportation of phosphate in muscle cell; and to 
mediate cell proliferation and differentiation into mature muscle fibres 
[Janssen 2002].  
 
Myostatin, a growth differentiation factor of the transforming growth 
IDFWRUEHWD7*)ǃIDPLO\LVIRXQGLQVNHOHWDOmuscle and is recognised to 
play a role in inhibiting muscle growth and differentiation. Girgis et al 
showed in C2C12 skeletal muscle cells treated with 25-OH-D3 that there 
was down regulation of myostatin with associated larger myotubules. 
[Garcia 2011]. This suggest the presence of CYP27B1 in converting the 
25-OH-D3 to 1,25-(OH)2-D3 and that may myostatin may be a target gene 
RI9'57KHHIIHFWVRIYLWDPLQ'DQG9'5RQRWKHU7*)ǃIDPLO\PHPEHUV
has been studied and shown in other organs such as how the skin reacts 
to injury [Luderer 2013] and inhibiting liver fibrosis [Ding 2013] 
supporting this pathway in skeletal muscles too.  
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Supplementation of vitamin D induces rapid changes in calcium 
metabolism of the skeletal muscle cell that cannot be explained by a slow 
genetic pathway suggesting a non-genomic pathway that vitamin D and 
VDR influences skeletal muscles [Janssen 2002].  
 
 
Figure 3 Genomic and non-genomic effects of vitamin D on muscle. Genomic 
effects are mediated by the formation of VDR-RXR heterodimers or VDR 
homodimers to affect muscle structure, function and metabolism. The non-
genomic effects are through calcium and phosphate homeostasis (adapted from 
Girgis 2013) 
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One big challenge in all this is the accurate identification of VDR in the 
target tissues, in this case skeletal muscles. Early studies began with 
using radio-labelled vitamin D and autoradiography [Stumpf 1995]. This 
radio-labelled assay is injected and followed via radiation signal to get an 
idea of its distribution within the body. Although sensitive, errors in VDR 
detection occurred as a result of receptor stability, ligand/receptor 
dissociation, or the presence of an endogenous ligand. Also, VDR 
expression is determined by vitamin D status and those deficient will 
expect a down regulation of VDR expression and this method of 
identification of VDR in vitamin D deficient animals may not accurately 
represent normal physiological VDR expression [Wang 2010]. More 
recently, immunoassays using VDR antibody has been used to detect VDR 
in target tissues. More than 10 VDR antibodies are commercially available 
but none has been systematically analysed for its sensitivity and 
specificity. Studies so far have not been conclusive in detecting VDR 
expression. For example, Bischoff et al using VDR 9A7 antibody showed 
the presence of VDR in skeletal muscles [Bischoff 2001] but Wang et al 
using VDR D6 antibody was unable to confirm the presence of protein for 
VDR, although VDR mRNA levels were detected [Wang 2011]. Wang et al 
in their review used multiple immunoassays with different antibodies 
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(IVG8C11, XVIE6E6, C20, D6, N20, H81, 9A7) and control samples on 
VDR knockout mice to study this further. They demonstrated that of the 
antibodies tested, the D6 had the ideal combination of high specificity and 
high sensitivity (Figure 4). They also conclude that due to a lack of well 
characterised VDR antibody, proper controls and standardised protocol 
have led to the contradictory findings from such studies on identifying 
VDR in target tissues, such as in skeletal muscles [Wang 2010].  
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Figure 4 Immunoblotting of mouse duodenal lysates from VDR KO Demay 
(lanes 1-4) or wild type (lane 5-9) mice. Blots were incubated with VDR 
antibodies (D6, IVG8C11, 9A7, N20, C20, H81, 39069). The blots were 
incubated with HRP-conjugated secondary antibodies. For the blots used to 
evaluate nonspecific reactions of secondary antibodies with tissue, the primary 
antibody was omitted. The HRP signal was developed by incubation of the blot 
with ECL solution and captured by X-ray film for increments of a variable time 
indicated in this figure. The VDR band on each blot was denoted by the 
arrowhead. The blots were also reprobed with an antibody to beta actin as a 
loading control (Adopted from Wang et al 2010) 
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1.6 Vitamin D and ageing 
Vitamin D deficiency is prevalent in older people. In the United Kingdom, 
the prevalence of vitamin D deficiency (25-OH-D3 less than 25nmol/L) of 
older people living in the community was as high as 15% and those in 
institutions was around 30% [Hirani 2005]. This prevalence is known to 
increase further especially in the winter. An older person produces less 
than 30% of the amount of vitamin D of a younger person when exposed 
to the same amount of sunlight [Holick 1989]. Low vitamin D levels in this 
group is multifactorial in nature through a combination of reduced 
sunlight exposure due to reduced mobility; reduced dietary intake; 
malabsorption; low skin thickness reducing previtamin D synthesis; and 
impaired hydroxylation in the liver and kidneys.  
 
We have established so far that the presence of VDR is paramount in the 
genomic and non-genomic function of vitamin D and its effect on skeletal 
muscle. However, not many studies have looked at the relationship 
between circulating vitamin D, VDR in skeletal muscle, human ageing and 
how it affects skeletal muscles. Rat models have shown that with age, 
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there is a decline in VDR expression in intestine, bone and kidneys 
[Montero 2005, Horst 1990]. Bischoff et al was able to demonstrate that 
VDR expression in human skeletal muscle declines with age using 
monoclonal VDR antibody 9A7 and that VDR expression was not related to 
serum 25-OH-D3 levels [Bischoff 2004]. Clinically, human ageing is 
associated with a progressive reduction in muscle mass, strength and 
function. The reduced VDR expression will reduce the functional response 
of the muscle cells to vitamin D.  The presence of vitamin D insufficiency 
which is highly prevalent in older people has clinically been shown to 
aggravate the problem further. This is likely due to the already impaired 
functional response due to limited VDR expression, but also the low 
circulating vitamin D will lead to further down regulation of VDR [Bischoff 
2001]. Over a period of time, this ongoing muscle loss of strength and 
function may lead to a phenomenon called sarcopenia that is currently 
stimulating a lot of research interest as it appears to be a key presence in 
frailty syndromes of older people, as well as being an outcome of the 
ageing and frailty process. Studies have shown that those deficient with 
25-OH-D3 levels less than 25nmol/L have lower muscle strength, 
especially in the proximal lower limbs [Visser 2003; Stockton 2011]. 
Glerup et al showed that reduced muscle strength and function begins 
even before bone disease sets in those who are vitamin D deficient 
36 
 
[Glerup 2000]. Muscle biopsies of patients deficient in vitamin D show 
atrophy of the type 2 fast acting muscle fibres. These muscle fibres were 
noted to have enlarged interfibrillar spaces and infiltration with fat, 
fibrosis and glycogen granules [Montero 2005]. The type 2 muscles are 
needed to react in the event of a loss of upright posture. This perhaps 
goes some way to explaining the increase incidence of falls in older people 
who are deficient in vitamin D. One study has shown that replacement 
with vitamin D increases the number of this type 2 muscle fibres 
[Sorensen 1979].   
 
Another explanation to the reduced muscle strength and function is the 
higher PTH levels in those who are vitamin D deficient. In rat models, PTH 
has been demonstrated to impair energy production, transfer and 
utilisation in muscle [Baczynski 1985]. PTH induces IL-6 production 
[Mitnick 2001] and raised IL-6 levels in older people are associated with 
lower muscle mass and strength [Visser 2002], and may influence 
sarcopenia [Payette 2003]. Secondary hyperparathyroidism has been 
noted in clinical studies to be a marker for reduced lower limb strength 
and that correcting it will restore muscle function [Vissier 2003]. 
However, this phenomenon may ultimately be related to the underlying 
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cause for the secondary hyperparathyroidisim which is vitamin D 
deficiency and correcting the deficiency also corrects the high PTH 
concentration.  
 
Falls in the elderly is associated with worse healthcare outcomes, i.e. 
recurrent falls, hospitalisation, institutionalisation, fracture, and mortality. 
Hence, much research has been done looking at the role of vitamin D 
supplementation to improve muscle strength to ultimately reduce to 
likelihood of suffering a fall. There is certainly good evidence now 
supporting the role of vitamin D in doses between 700 ± 1000 IU in 
prevention of falls in those that are deficient in vitamin D [Bischoff-Ferrari 
2009; Cameron 2012]. This further supports the role that vitamin D plays 
in maintaining muscle function integrity.  
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1.7 Thesis aims 
There is a paucity of studies into how human ageing and serum vitamin D 
levels affect VDR expression in skeletal muscle. Only one study that has 
been described earlier has so far examined VDR expression in human 
muscle tissue in relation to age using 2 different muscle groups (gluteus 
medius or transversospinalis muscle) [Bischoff 2004]. This present thesis 
aims to examine the relationship between human ageing and circulating 
vitamin D level to VDR expression. It is hypothesised that ageing and 
lower circulating levels of vitamin D is associated with lower expression of 
VDR and the genes dependent on vitamin D in human skeletal muscles. 
This study will contribute to our current understanding of whether VDR 
expression is affected by either the ageing process or low serum vitamin 
D levels. Besides that, the presence of VDR in skeletal muscle has been 
subject to much debate mostly due to the lack of specificity of the 
antibodies used to detect it either by Western blotting or 
immunohistochemistry. Hence, this thesis aims to contribute to this 
debate demonstrating VDR to be central in the way vitamin D influences 
skeletal muscle function. By relating vitamin D levels (serum 25-OH-D3 
concentrations) to age and expression of VDR, and some of its target 
genes (sirt1, 33$5Į33$5įDQGP\RVWDWLQLQVNHOHWDOPXVFOHWKLVWKHVLV
aims to increase our understanding of the function of skeletal muscle. In 
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the near future, a better understanding of this can hopefully be translated 
into a clinical setting that will further guide how we treat either vitamin D 
deficiency to improve muscle function, reduce falls and fractures.  
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CHAPTER 2 
METHODS 
 
2.1 Study design 
This is a prospective cross-sectional study involving blood and muscle 
sampling of young and older groups of participants. 
 
2.2 Participants 
Twenty six participants were recruited to the study. Eight young 
participants (18 ± 25 years) were recruited from the University of 
Nottingham student population through the human physiology lab and 
notice board advertisements. Eighteen older participants (>65 years) 
were recruited from the bone health clinic, Queens Medical Centre, 
Nottingham University Hospitals NHS Trust. The older group was divided 
into two groups consisting of those vitamin D sufficient, defined as a 
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circulating level of 25-OH-D3 >50nmol/L, and those vitamin D insufficient 
participants, defined as a circulating level of 25-OH-D3 QPRO/ 
 
Potential participants were invited to participate in the study voluntarily. 
After written consent was obtained, all participants underwent a medical 
screening which included a medical questionnaire for any potential 
exclusion criteria and having a blood sample taken. Blood pressure 
measurements were also performed during the screening process and the 
young participants had an electrocardiogram performed. Those excluded 
were taking corticosteroids, had a diagnosis of chronic kidney disease 
(defined by a serum creatinine level >250mmol/L), had a diagnosis of a 
neuromuscular disease, overt diabetes mellitus, or a condition that is 
known to affect vitamin D metabolism.  
 
2.3 Muscle biopsy 
Participants were asked to return on a separate occasion for a muscle 
biopsy of the thigh (vastus lateralis) at the human physiology laboratory. 
Current techniques to obtain muscle specimen includes an invasive open 
biopsy approach, the use of a Weil-Blakesley conchotome (Figure 5, a 
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forcep consisting of a sharp biting tip) and the more common Bergstrom 
needle (Figure 6, which consists of a sharp trochar, a cutting cannula and 
a pushing rod to expel the muscle specimen) [Patel 2012]. These 
approaches involve either an incision or a semi-incision/semi-open 
approach that can cause pain, discomfort and leave the potential for 
scarring. Hence, minimally invasive approaches, similar to biopsy studies 
of breast, prostate or kidney tissues offer an attractive option in this 
research. Although this technique still involves piercing the skin and fascia 
to get to the muscle, the smaller incision means it is less likely to scar, 
cause discomfort and will heal quicker. Besides that, there is evidence 
that this technique of minimally invasive biopsy is comparable to the 
more common semi-open Bergstrom approach, which is considered the 
gold standard approach [Hayot 2005].  
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Figure 5 Weil-Blakesley conchotome for obtaining muscle biopsy (from Patel HP 
et al 2012) 
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Figure 6 Bergstrom needle (from Patel HP et al 2012). (A) Components of the 
biopsy needed include (1) Trocar (2) Cutting cannula (3) Clearing probe/rod. (B) 
Assembled for biopsy, with cutting cannula inserted within the trocar. A 20ml 
syringe can be connected to the cutting cannula to increase the yield of tissue by 
suction. (C) Cutting window visible. (D) Window with cutting cannula fully 
depressed 
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This minimally invasive or microbiopsy approach uses a 16 gauge core 
disposable biopsy needle loaded on to a spring system reusable 
instrument, the Magnum® Biopsy System (Figure 7). Participants are 
asked to lie down with the preferred thigh for biopsied exposed. Upon 
cleaning the skin with an iodine based cleaning solution, local 
anaesthesia, i.e. 1% lignocainse, is first used to anaesthetise the skin. An 
incision of the skin and fascia is made. The biopsy needle inserted into the 
0DJQXPµJXQ¶LVWKHQLQVHUWHGSHUSHQGLFXODUWRWKHPXscle. Muscle tissue 
is obtained by activating the trigger button which activates the needle and 
collects the specimen. The muscle tissue is removed from the biopsy 
needle using a sterile scalpel and immediately frozen in liquid nitrogen. 
Pressure and a dressing were applied to the wound. There was no 
restriction to daily activities post procedure. Participants were asked to 
avoid exposing the wound to water for 48 ± 72 hours after the biopsy.  
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Figure 7 Magnum biopsy system (from Hayot M et al 2005). The top figure 
shows the disposable biopsy needle loaded on to a spring system of the Magnum 
JXQ7KHERWWRPILJXUHVKRZVWKH0DJQXPµJXQ¶LQVHUWHGSHUSHQGLFXODUWRWKH
muscle to obtain the muscle specimen. 
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2.4 Blood analysis 
Blood samples for the determination of serum calcium, PTH and 25-OH-D3 
concentrations were collected into EDTA tubes and allowed to clot. Plasma 
and serum were separated by low speed centrifugation (15 min at 3000g 
DWÛ&DQGVWRUHGDW-ÛXQWLODQDO\VLV$OLTXRWVRIserum were sent for 
analysis to the pathology department, Nottingham University Hospitals 
(NUH) NHS Trust. Both 25-OH-D3 and parathyroid hormone were 
quantified using two side sandwich competitive using direct chemi-
lumunescent on the Siemens ADVIA Centaur system.  Calcium levels were 
quantified using photometric colorimetric test method measured on the 
Beckman AU clinical chemistry analyser.  
 
2.5 RNA extraction and quantification; and cDNA synthesis 
Muscle biopsy samples were stored in liquid nitrogen. Total RNA was 
extracted from the frozen muscle tissue using the method of Chomczynski 
and Sacchi [Chomczynski 1987] using TRIzol reagent (Invitrogen, Paisley, 
UK). 800µL of Trizol (Invitrogen) and 20µL glycogen were added to 
around 15mg of tissue which was homogenised using Polytron for 30 
seconds and incubated at room temperature for 5 minutes. After that, 
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156.8µL chloroform and 3.2µL isoamyl alcohol were added to the samples 
and shaken vigorously followed by vortex for a few seconds. After being 
left at room temperature for 2-3 minutes, the samples were then 
centrifuged at 12,000g for 15 minutes at 4ÛC. The aqueous phase 
(500µL) containing the RNA was transferred to a RNAse free eppendorf 
tube and kept overnight in 400µL isopropanol at -20ÛC to allow RNA 
precipitation. The remaining lower organic phase of the RNA extraction 
was kept for subsequent protein extraction (see section 2.6). The next 
day, the samples were centrifuged at 12,000g for 15 minutes at 4ÛC. 
Supernatant was removed and pellets were air-dried and then washed by 
adding 800µL of 75% EtOH and vortexing for a few seconds, and then 
spun again at 10,000g for 10 minutes. The supernatant was removed and 
any remaining EtOH was pipetted off. The pellets were air-dried for 5 
minutes, re-dissolved in 30µL of RNAse-free water and quantified in 
duplicate using a Nanodrop ND-100 (Thermo Fisher Scientific, Delaware 
USA). Reverse transcription (RT) was carried out from 500 ng of total 
RNA using the SuperScript III cDNA kit (Invitrogen, Paisley, UK) 
accordinJWRPDQXIDFWXUHU¶VLQVWUXFWLRQV.  Briefly, ten µL of RNA, 10 µl of 
RT Reaction mix and 2 µl of RT enzyme were mixed, centrifuged for few 
seconds and incubated at 25ºC for 10 minutes and then at 50ºc for 30 
minutes. The reaction was terminated at 85ºc at 5 minutes; 1 µl of E.coli 
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RNAase H was then added and samples incubated for 20 minutes at 37ºc. 
20 µl of cDNA was diluted eight times with RNAse free water. 
 
2.6 Real time quantitative PCR  
Taqman primers and probes sets were designed using Primer Express 
version 2.0 software (Applied Biosystems, Warrington, UK) and obtained 
from Applied Biosystems, UK. Their sequences are presented in Table 1. 
Real-time PCR measurements were performed in triplicate using PCR 
Universal Master Mix (Applied Biosystems) in a Micro- Amp 96-well plate 
using an ABI Prism 7000 Sequence Detection System (Applied 
Biosystems, UK). The quantification of expression of each gene relative to 
D-actin was determined using the method described in Appendix 2. 
Standard curves were produced from serial dilutions of a pooled sample of 
cDNA from all individual samples. Twenty five microlitre reactions were 
UXQLQWULSOLFDWHDQGHDFKWXEHFRPSULVHGǋORIF'1$WHPSODWHǋO
RI HDFK SULPHU  ǋO RI SUREH  ǋO of Taqman Universal PCR 
MaVWHUPL[DQGǋO51DVH-free water.  Cycling conditions included an 
initial hold of 2 min at 50qC, followed by a hold of 10 min at 95qC, and 
then 40 cycles of 95qC for 15 sec, 60qC for 1 min.     
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Table 1. Sequences for primers and Taqman probes used for real-time PCR 
 
Gene Forward Primer Probe Reverse Primer 
 
VDR 
 
GACCCCACCTACTCCGACTTCT 
 
CCAGTTCCGGCCTCCAGTTCGTG 
 
GGCTCCCTCCACCATCATT 
 
Sirt1 
 
TGCGGGAATCCAAAGGATAA 
 
TCAGTGTCATGGTTCCT 
  
  CAGGCAAGATGCTGTTGCA 
 
Myostatin 
 
GATGAGAATGGTCATGATCTTGCT 
 
TAACCTTCCCAGGACCAG 
 
AAAAACGGATTCAGCCCATCT 
 
33$5Į 
 
GCTTCCTGCTTCATAGATAAGAGCT
T 
 
AGCTCGGCGGCACAACCAGCA 
 
CACCATCGCGACCAGATG 
 
33$5į 
 
TGCGGCCATCATTCTGTGT 
 
ACCGGCCAGGCCTCATGAACG 
 
CAGGATGGTGTCCTGGATAGC 

D-Actin  
 
 
GAGCCGAGAGTAGCAGTTGTAGCT 
 
CCCGCCCAGAAACTAGACACAATGTGC 
 
GCGGTGGTCTCGTCTTCGT 
 
2.7 Protein extraction 
Protein extraction was performed from the organic phase left over after 
the RNA extraction method using the Trizol reagent (see Appendix 1 for 
the detailed method). Briefly, after removing and discarding the 
interphase (that contained the DNA), 1.5ml Isopropanol per ml of Trizol 
originally used was added to the organic phase (lower pink phase that 
contained the proteins) This was mixed and left at room temperature for 
10 minutes to allow the protein to precipitate. Tubes were then 
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centrifuged at 12,000g for 10 minutes and then 2ml of wash solution 
(0.3M guanidine in 95% EtOH) was added before being mixed on a daisy 
wheel for 20 minutes at room temperature. This was followed by 
centrifugation at 7,500g for 5 minutes at 4oC. Pellets were then washed 
with 100% ethanol and resuspended by adding 400µl Protein 
Resuspension Solution, sonicated on ice and stored for further analysis. 
Quantification of protein concentrations was performed using the Bovine 
Serum Albumin Protein Assay (Pierce, Perbio, USA) using a 
spectrophotometer (SpectraMAX 190 Molecular Devices). 
 
2.8 Western Blotting 
Twenty micrograms of total muscle lysate proteins were separated using 
10% sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-
PAGE). The gels were electrophoresed on a vertical dual plate unit 
(Fisher, Loughborough, UK) and the separated proteins were 
electroblotted overnight to Hybond-C nitrocellulose membranes 
(Amersham Biosciences, UK). After blocking with 5% (w/v) Marvel (milk) 
in a solution of 0,1% (w/v) Tween 20  in Tris Buffered Saline (TBS-T)  for 
1h at room temperature, the membranes were incubated for 1h with a 
52 
 
primary antibody for human VDR (dilution 1:250, GR37, Oncogene 
Research Products, USA or VDR-D6, Santa Cruz, sc13133) and then on a 
separate day for the endogenous control (D-actin, dilution 1:2,000, A-
2066, Sigma-Aldrich Co). After washing for 4 x 10 minutes in 0.5% (w/v) 
Marvel TBS-T the membranes were incubated for 1h at room temperature 
with secondary antibodies linked to HRP, anti-rat (dilution 1:2,000, 
Amersham Biosciences, UK) and anti-rabbit (dilution 1:2,000, Amersham 
Biosciences, UK) detecting the primary antibodies for  VDR and D-actin, 
respectively. After washing (as above) all immunoreactive proteins were 
visualised using ECL and Hyperfilm (Amersham Biosciences, UK) with the 
resulting bands quantified using densitometry performed using the 
Quantity One® 1-D Analysis Software version 4.5 (Bio-Rad Laboratories, 
Inc., USA). 
 
2.9 Statistical analysis 
Participant demographics were described for the young and older group. 
Mean and standard error or the mean (SEM) was used to describe age 
and calcium levels. Median and interquartile range (IQR) was used to 
describe the 25-OH-D3 levels due to the skewed results obtained within 
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the young group. Data are presented as standard error of the mean 
(SEM) for VDR mRNA, myostatin mRNA, Sirt1 mRNA33$5ĮDQG33$5Ǆ
normalised to D-actin.  One way analysis of variance (ANOVA) for 
parametric data and Kruskal-Wallis test for non-parametric data were 
used to analyse differences between groups [young participants, older 
participants vitamin D sufficient (25-OH-D3 >50nmol/L) and older 
participants vitamin D insufficient (25-OH-D3 QPRO/@Statistical 
significance was defined as a p value of <0.05. When statistical difference 
was detected, post-hoc tests using t-test for parametric data and Mann-
Whitney U test for non-parametric data, with Bonferroni corrections were 
conducted within groups (young group vs older sufficient group; young 
group vs older insufficient group; and older sufficient group vs older 
LQVXIILFLHQWJURXSWRORFDWHWKHGLIIHUHQFHV3HDUVRQ¶VFRUUHODWLRQ
coefficient was used to describe the strength of the relationship between 
circulation vitamin D and target genes.  
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CHAPTER 3 
RESULTS 
Participant characteristics are described in Table 2. The young group was 
made up of males only and in the older group, the participants were 
almost entirely made up of female volunteers. The older sufficient group 
had higher 25-OH-D3 levels than the older insufficient group and the 
young group (P=0.00). However, there was no significant difference in its 
levels between the older insufficient and young groups (p=0.14). Most of 
the participants in the young group were deficient in vitamin D levels with 
a median 25-OH-D3 of 16nmol/L (range 12 ± 97). All participants had 
calcium levels within the normal range for the laboratory analysis with no 
differences observed between groups. PTH values were higher in the older 
25-OH-D3 insufficient group compared to the sufficient group (p=0.02).  
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Table 2 Participant characteristics (age, gender, body mass index (BMI) and 
circulating levels of 25-OH-D3, calcium and parathyroid (PTH) 
 
Young group 
(n=8) 
Older 
sufficient 
group (n=10) 
Older 
insufficient 
group (n=8) 
p-value 
Age, mean 
(SEM) 
23.5 (1.1) 76.2 (2.1) 75.9 (2.0) 0.00 
Male/Female 8/0 10/0 7/1 - 
Body mass 
index, mean 
(SEM) 
23.09 (1.3) 25.7 (1.7) 26.8 (4.3) 0.54 
25-OH-D3, 
nmol/L, 
median (IQR) 
16 (29.3)  62 (21.3) 38 (14.5) 0.001# 
Calcium, 
mmol/L, 
mean (SEM) 
2.36 (0.8) 2.45 (0.8) 2.40 (0.8) 0.07 
PTH, pg/mL, 
mean (SEM) 
-* 39.57 (15.0) 68.86 (26.0) 0.02 
#Older sufficient group had higher 25-OH-D3 levels than the older insufficient 
group and the young group. There was no statistically significant difference in its 
levels between the older insufficient and young groups (p=0.14). *PTH was not 
done in the young group as NUH Hospitals Trust laboratory only runs PTH 
analysis in EDTA plasma specimens (which were not collected for this group). 
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Table 3 describes the mean ± SEM of the 5 genes analysed within the 3 
groups. Within the defined level of significance (p<0.05), there were 
differences between groups in 9'5P51$6LUWP51$DQG33$5įEXW
QRWP\RVWDWLQDQG33$5Į mRNA.  
Table 3 6NHOHWDOPXVFOHP51$FRQWHQWRI9'5P\RVWDWLQ6LUW33$5ĮDQG
33$5įUHODWLYHWRĮ-actin mRNA content in the 3 groups, young participants (18-
\HDUVROGROGHUSDUWLFLSDQWV\HDUVROGvitamin D sufficient (25-OH-D3 
>50nmol/L) and older participants vitamin D insufficient (25-OH-D3 QPRO/.  
 
 
Young group 
(n=8) 
Older 
sufficient 
group (n=8) 
Older 
insufficient 
group (n=10) 
p-value 
VDR mRNA/Į-
actin mRNA 
6.84±0.93 12.66±1.53 a 14.01±2.08 a 0.01* 
Myostatin 
mRNA/Į-actin 
mRNA 
10.11±0.75 9.98±1.13 11.73±1.83 0.58 
Sirt1 mRNA/Į-
actin mRNA 
8.58±0.52 12.62±0.81 b 11.26±0.95 0.00* 
33$5Į/Į-actin 
mRNA 
5.53±0.35 6.93±0.52 5.86±0.37 0.07 
33$5į/Į-actin 
mRNA 
4.99±0.23 8.96±0.63 c 7.91±0.83 c 0.00* 
Data expressed as mean±SEM. P-value calculated based on one way ANOVA. 
*denotes p-value <0.05. a Higher expression of VDR mRNA in older sufficient 
and insufficient group vs younger group. b Higher Sirt1 mRNA expression in older 
sufficient group vs younger group. c +LJKHUH[SUHVVLRQRI33$5įLQROGHU
sufficient and insufficient group vs younger group. 
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There was a difference in skeletal muscle VDR mRNA content between the 
young participants and the older participants sufficient of vitamin D 
(p=0.01); and young participants and the older participants insufficient of 
vitamin D (p=0.01). Specifically, VDR mRNA expression was higher in the 
older participants compared to the younger group regardless of circulating 
levels of vitamin D. However, there was no difference between the two 
older participant groups (p=0.61) (Figure 8). When sirt1 was analysed, 
the only statistically significant difference was between the younger 
participants and the older group who were vitamin D sufficient (p=0.001) 
with higher expression in the older cohort (Figure 10). When the older 
insufficient group was compared to the younger group, there was a 
tendency towards a higher expression in the older group (p=0.02). There 
waVDGLIIHUHQFHLQ33$5įEHWZHHQWKH\RXQJHUSDUWLFLSDQWVDQGERWKWKH
older sufficient (p=0.00) and older insufficient group (p=0.00), with the 
young cohort showing lower levels of expression (Figure 12). There was 
no difference in skeletal muscle PPARD mRNA content between groups 
although there was a tendency (P=0.07) for higher expression in the 
older sufficient group when compared with the other 2 groups (Figure 
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11).  There was no statistical difference in skeletal muscle myostatin 
mRNA content between groups (Figure 9). 
59 
 
 
Figure 8 Bar graph representing the 3 groups with skeletal muscle VDR mRNA 
normalised to alpha actin mRNA content with each bar representing the 
respective mean. Error lines represent SEM of each group. *One-way ANOVA 
performed between young participants and older participants group showed 
statistical significance of p-value=0.01.  
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Figure 9 Bar graph showing skeletal muscle myostatin mRNA normalised to 
alpha actin mRNA content with each bar representing the respective mean. Error 
lines represent SEM of each group.  
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Figure 10 Bar graph representing the 3 groups with skeletal muscle sirt1 mRNA 
normalised to alpha actin mRNA content with each bar representing the 
respective mean. Error lines represent SEM of each group. *One-way ANOVA 
performed between young participants and older participants in the vitamin D 
sufficient group showed statistical significance of p-value<0.01. 
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Figure 11 Bar graph showing VNHOHWDOPXVFOH33$5ĮQRUPDOLVHGWRDOSKDDFWLQ
mRNA content with each bar representing the respective mean. Error lines 
represent SEM of each group. 
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Figure 12 %DUJUDSKUHSUHVHQWLQJWKHJURXSVZLWKVNHOHWDOPXVFOH33$5į
normalised to alpha actin mRNA content with each bar representing the 
respective mean. Error lines represent SEM of each group. *One-way ANOVA 
performed between young participants and both groups of older participants in 
showed statistical significance of p-value<0.01.  
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The scatter plots shown in figures 13 ± 17 describe the relationship 
between circulating levels of 25-OH-D3 nmol/L and skeletal muscle gene 
expression. There was not any overall strong relationship between 
circulating vitamin D levels and any of the genes expressed. When the 
relationship between circulating 25-OH-D3 and VDR mRNA was examined 
in the older participant group as a whole (sufficient and insufficient) 
(Figure 13) and young participants (Figure 14) separately, it 
demonstrated a moderate non-significant association (r=0.56) in the 
young group but not in the older group. There were also moderate 
relationships between increasing circulating 25-OH-D3 levels and lower 
myostatin mRNA content (r=-0.63) and higher sirt1 mRNA (r=0.55) in the 
younger participants only. With respect to PPARs, circulating 25-OH-D3 
VKRZHGZHDNDVVRFLDWLRQVZLWK33$5ĮLQ\RXQJDQGROGHUSDUWLFLSDQWV
U DQGU UHVSHFWLYHO\DQG33$5įU DQGU 
respectively).  
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Figure 13 Relationship between skeletal muscle VDR mRNA content normalised 
to alpha actin mRNA content, and serum 25-0H-D3 levels (nmmol/L) in older 
participants, n=18 (A) and young participants, n=8 (B). 
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Figure 14 Relationship between skeletal muscle myostatin content 
normalised to alpha actin mRNA content, and serum 25-0H-D3 levels 
(nmmol/L) in older participants, n=18 (A) and young participants, n=8 
(B). 
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Figure 15 Relationship between skeletal muscle sirt1 content normalised to 
alpha actin mRNA content, and serum 25-0H-D3 levels (nmmol/L) in older 
participants, n=17 (A) and young participants, n=8 (B). 
68 
 
 
 
Figure 16 Relationship between skeletal muscle 33$5Į content normalised to 
alpha actin mRNA content, and serum 25-0H-D3 levels (nmmol/L) in older 
participants, n=18 (A) and young participants, n=8 (B). 
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Figure 17 Relationship between skeletal muscle 33$5į content normalised to 
alpha actin mRNA content, and serum 25-0H-D3 levels (nmmol/L) in older 
participants, n=18 (A) and young participants, n=8 (B). 
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Figure 18 6FDWWHUSORWVKRZLQJWKHUHODWLRQVKLSEHWZHHQVLUWDQG33$5į
expression relative to VDR expression in all older participants, n=18.  
 
)LJXUHVKRZVWKHUHODWLRQVKLSEHWZHHQVLUWDQG33$5įZLWK9'5
7KHUHLVDPRGHUDWHSRVLWLYHDVVRFLDWLRQEHWZHHQ33$5į and VDR mRNA 
(r=0.62) but not with sirt1 (r=0.15).  
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Western blotting to quantify VDR protein in human skeletal muscle was 
unsuccessful. The first antibody used VDR 9A7 did not detect any bands. 
Based on existing literature [Wang 2010] which identified the D6 antibody 
being highly specific and more sensitive, it was subsequently purchased 
and used in new blots generated from protein samples derived from the 
Trizol extraction. However, that attempt was unsuccessful in detecting the 
VDR protein. In further studies, we were able to detect the VDR protein as 
a 53kDa band in protein homogenates extracted directly from human 
skeletal muscle. The reason protein samples from TRIzol extraction were 
used in this study was because the amount of muscle sample obtained 
using the microbiopsy approach was limited and not sufficient to perform 
separate RNA and protein extractions.   
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CHAPTER 4 
DISCUSSION 
This thesis set out to investigate the relationship between circulating 
vitamin D, ageing  and skeletal muscle VDR expression by comparing 3 
different cohorts; young participants, older participants who were vitamin 
D sufficient and older participants who were vitamin D insufficient. It 
should be noted that circulating 25-OH-D3 levels were low in the young 
group (which was meant to act as the control group in this study). 
Samples were obtained over the course of the year with 4 taken during 
the summer period (June ± July) and the rest between October and 
December. There is existing literature that has shown that 
hypovitaminosis D is highly prevalent even in young adults, especially in 
the winter period [Mithal 2009, Tangpricha 2002]. One study identified 
that the prevalence of vitamin D deficiency is between 11 ± 30% 
depending on the time of the year the sample was obtained [Tangpricha 
2002]. In the present study, the circulating 25-OH-D3 levels in the young 
subjects were not statistically different compared with the older 
insufficient group.  
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The findings from the present investigation demonstrated that skeletal 
muscle VDR mRNA expression was higher in the older sufficient group and 
the older insufficient group compared to the younger group. VDR is 
central to the effect that vitamin D plays within skeletal muscle and 
existing literature suggests that higher levels of 25-OH-D3 upregulate VDR 
expression. Solvsten et al demonstrated that when keratinocytes where 
incubated with 1,25-(OH)2-D3, it resulted in an increase in VDR protein 
and mRNA levels [Solvsten 1997]. The maximal increase in protein levels 
peaked after 8 hours of incubation where the levels rose to 177% in 
undifferentiated keratinocyte cultures and 268% in differentiated 
keratinocyte cultures compared to the levels in unstimulated cells at the 
start of the incubation. This rise above basal levels were sustained even 
up to 24 hours post incubation. There was also a dose dependent 
upregulation of VDR mRNA expression with higher levels of 1,25-OH2-D3. 
The vitamin D-VDR ligand subsequently binds to VDRE response elements 
(VDRE) to affect gene transcription. Hence, the upregulation seen may be 
related to the way this ligand affects and induces upregulation of VDR 
mRNA; or it may just be due to the direct effect vitamin D has on the 
promotor of the VDR gene [Solvsten 1997].  Our study has revealed no 
statistically significant difference in VDR mRNA in the two older groups 
(sufficient and insufficient); and despite similar circulating 25-OH-D3 
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levels in the young participants and older insufficient group, there was 
still higher content of VDR mRNA in the older group. Figure 13 
demonstrated a weak negative relationship between circulating 25-OH-D3 
and VDR mRNA expression in older participants. However, in the younger 
participants, there was a moderate positive relationship between 
circulating 25-OH-D3 and VDR mRNA expression. Hence, an alternative 
explanation is that VDR expression may be upregulated by the ageing 
process itself and that higher levels of vitamin D may be associated with 
higher VDR mRNA in young subjects but not the older participants. Ageing 
may be an intrinsic natural upregulator to improve vitamin D function in 
tissues, such as skeletal muscle, as lower vitamin D synthesis happens 
with advancing age. Due to that, an upregulation of VDR may be needed 
to facilitate the function of vitamin D. However, this goes against animal 
studies that have shown a decline in VDR expression with age. Montero et 
al and Horst et al have shown in rat models reduced VDR expression in 
intestine, bone and kidneys reduced with advancing age [Montero 2005, 
Horst 1990].  Bischoff in their paper also demonstrated a decline in VDR 
expression in human skeletal muscle with advancing age [Bischoff 2004]. 
However, in their study, muscle was obtained from either the gluteus 
medius or transversospinalis muscle; and the specimens incubated with 
VDR 9A7 antibody and later analysed using immunohistochemical 
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methods. They also had relatively younger patients within their cohort 
compared to our study. Another study presented recently as an abstract 
at the Federation of American Societies for Experimental Biology showed 
VDR in human skeletal muscle to be strongly associated with circulating 
25-OH-D3 levels in older people [Pojednic 2013]. Our study was unable to 
show a relationship between circulating levels of vitamin D and VDR in 
VNHOHWDOPXVFOHELRSVLHVRIROGHUSHRSOH%LVFKRII¶VVWXG\DOVRIDLOHGWR
show and association between VDR expression and circulating 25-OH-D3 
levels [Bischoff 2004].  
 
Mouse skeletal muscle cells C2C12 is widely used to study genes that 
regulate muscle growth and differentiation [Garcia 2011]. Garcia et al 
were able to demonstrate that C2C12 muscles cells when incubated with 
1,25-(OH)2-D3, had increased expression of VDR mRNA by 15.1 and 6.4 
fold at day 1 and day 4 respectively compared with controls (no 1,25-
(OH)2-D3 incubation); enhanced myogenesis, as shown with an increase in 
myogenic markers, e.g. MyoD and desmin; reduced mRNA expression of 
myostatin by 2.5 and 10 fold on day 4 and 7 respectively; and an 
increase in follistatin expression, an inhibitor of myostatin [Garcia 2011].  
These findings highlight the crucial role vitamin D play in muscle 
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myogenesis via its interaction with VDR. However, the present study did 
not show any difference in myostatin mRNA expression between the older 
sufficient and insufficient groups which points towards circulating 25-OH-
D3 levels not affecting its expression. Given that similar VDR levels were 
observed in both the older sufficient and insufficient groups, it appears 
that myostatin expression is associated with the level of VDR expression 
rather than the amount of circulating vitamin D. However, myostatin 
expression in skeletal muscle is also regulated by other factors, such as 
ageing, exercise, and other myogenic regulatory factors, although in the 
present study ageing per se did not appear to affect myostatin expression 
as the younger group had similar myostatin levels to the older 
participants.  
 
When other genes that are known targets of vitamin D were studied, 
significant differences were detected between the older sufficient group vs 
WKH\RXQJHUJURXSIRUVLUWDQG33$5į,QRXUVWXG\VLUWZDV
significantly more expressed in older sufficient group compared to the 
younger group and there was a tendency for it to be more expressed in 
the older insufficient group compared to the younger group. When both 
older groups with different vitamin D levels were compared, there was no 
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statistical difference in sirt1 expression. An et al in their study were able 
to link the role of vitamin D/VDR with sirt1 by showing how VDR interacts 
with FoXO proteins and its regulator sirt1 [An 2010]. They were able to 
demonstrate how vitamin D/VDR induces sirt1 and the phosphatase-
dependent dephsphorylation and activation of FoxO function; and that 
vitamin D and FoXO share similar target genes.  Existing studies have 
also shown that sirt1 overexpression lead to longer life span and a delay 
in the ageing process in mouse models [Price 2012, Satoh 2013]. One 
likely explanation to this is that sirt1 expression leads to better 
mitochondrial structure and function, as it is the mitochondrial 
dysfunction that has been recognized to be associated with the ageing 
process and the development of diseases, such as cancer [Erol 2007]. 
Price et al described in C2C12 muscle cells how sirt1 is associated with an 
increase in mitochondrial membrane potential and cellular ATP content 
and treatment with sirt1 inhibitor or knockdown sirt1 reduces it. 
Treatment with resveratrol which is dependent on sirt1 for its function 
increased mRNA expression of genes responsible for stimulating 
mitochondrial biogenesis, e.g NRF-1 and NRF-2. Hence, one can conclude 
that the higher sirt1 levels in older participants might be related to the 
ageing process itself as opposed to circulating vitamin D levels.  
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:KHQ33$5VZHUHH[DPLQHGWKHUHZDVKLJKHUH[SUHVVLRQRI33$5įP51$
in both older sufficient and insufficient groups when compared with the 
\RXQJHUJURXSDQGWKHUHDSSHDUHGWREHDWHQGHQF\IRUKLJKHU33$5Į
expression in older vitamin D sufficient group compared to the younger 
JURXS33$5įLVQRWHGWREHPRUHDEXQGDQWLQVNHOHWDOPXVFOH>(KUHQERUJ
2009].  Again, very much like sirt1, PPARs have a role in the ageing 
process being involved in the suppression of the inflammatory process 
seen with advancing age [Chung 2008]. Besides that, it is also involved in 
cellular growth, glucose homeostasis, insulin sensitivity and lipid 
metabolism [Erol 2007]. PPARs exert its effects by forming heterodimers 
with RXR, similar to VDR acting on specific DNA regions of target genes. 
This complex of PPAR/VDR-RXR bind to their specific response elements 
and have interconnected pathways that regulate the target genes and 
their  transcription [Matsuda 2013]. This crosstalk link between VDR and 
PPAR means that both are DEOHWRLQIOXHQFHHDFKRWKHU¶VVLJQDOOLQJ
pathway and that PPAR may act as a coactivator in the way vitamin D-
VDR exerts its genomic effects. In one study using kidney tissue from rat 
models, it showed downregulation of PPAR (33$5ĮDQGǄGXHWRWKH
ageing process. Compared with young rats, older rats showed decreased 
PPARĮand PPARǄ mRNA and nuclear protein levels; by 30% and 46%, 
and 53% and 84% respectively [Sung 2004]. The author further 
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highlighted the limited number of studies that have looked at the 
influence of ageing on PPARs. Iemitsu et al studied the influence of ageing 
RQFDUGLDFPXVFOHLQUDWVDQGGHVFULEHGDUHGXFWLRQLQ33$5ĮZLWKDJH
[Iemitsu 2002] but Chao et al using liver tissue from rat subjects did not 
show DGHFOLQHLQ33$5ĮZLWKDJH>&KDR@Mazatti et al using mice 
PRGHOVZHUHDEOHWRGHWHFWXSUHJXODWLRQRI33$5įGXULQJSHULRGVRI
muscle unloading; and downregulation of the other PPAR isoforms. 
Although this was transient in nature with levels back to baseline at day 
12, it points towards a metabolic response to maintain metabolic 
flexibility and fuel utilization [Mazzatti 2008]. This may explain the ageing 
upregulation of PPARs in the older subjects noticed in the present study.  
 
Limitations 
Vitamin D deficiency was prevalent within our young participant cohort. 
As described earlier, there is existing literature that has shown that low 
vitamin D levels are prevalent within a young adult cohort. Besides that, 
there were gender differences between the groups as well. We were only 
successful in recruiting young male volunteers; and female older 
volunteers. The invasive procedure, i.e. muscle biopsy that needed to be 
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performed as part of this study has most likely deterred young female 
participants to the study. As we were recruiting older participants in a 
bone health/osteoporosis clinic, where it is predominantly made up of 
female patients, meant that we were unsuccessful in recruiting more men. 
Gender variation of vitamin D levels has not been conclusive as vitamin D 
level is strongly influenced by factors such as geographical 
location/latitude and skin pigmentation [Hagenau 2009].  One UK 
epidemiological study did described hypovitaminosis D to be more 
prevalent in community living women than men [Hirani 2005]. However, 
there is a paucity of data in the literature on how gender itself may 
influence human skeletal VDR expression. Therefore it is difficult to 
conclude whether the imbalance in gender recruitment in the present 
study may have had an effect on WKLVVWXG\¶VILQGLQJV 
Another limitation within this study was the unsuccessful effort in protein 
determination of VDR despite using 2 different VDR antibodies. We were 
unable to get a good signal on western blot. As described earlier, 
additional studies were performed where protein was directly extracted 
from the skeletal muscle and VDR was detected. As there was limited 
tissue specimen and time constraints brought on by the need to submit 
this thesis, this part of the study was not re-attempted. However, the 
detection of VDR mRNA and evidence of VDR protein being present in 
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skeletal muscle from previous experiments done locally (unpublished 
observation) and existing literature [Bischoff 2001] supports the presence 
of VDR in human skeletal muscle. Girgis et al in their review highlighted 
the challenges in VDR detection in skeletal muscle due to the difference in 
experimental conditions; possibility of tight protein binding of VDR to 
DNA; low levels of VDR may be in itself enough for significant muscle 
function; and that VDR expression may be different in difference species 
and its expression varies depending on the varying stage of muscle 
growth [Girgis 2013].  
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CONCLUSION 
The findings from the present study support the presence of the VDR 
gene in human skeletal muscle and extend this finding by showing no 
significant association between its level of expression and circulating 
levels of 25-OH-D3.  Indeed, similar VDR, sirt1, myostatin and PPARs 
mRNA levels were observed in skeletal muscle from older vitamin D 
sufficient and insufficient subjects. Interestingly, higher expression of 
VDR and 33$5įP51$ was observed in both older sufficient and 
insufficient groups when compared with the younger group. There was 
also higher Sirt1 mRNA expression in the older sufficient group when 
compared to the younger group.  When both the young group (that was 
predominantly vitamin D deficient) was compared with older participants 
that were also deficient, skeletal muscle VDR gene expression was still 
higher in the latter group. This suggests that the ageing process per se 
may be influencing (by upregulation) the expression of the VDR and 
33$5į genes at least under conditions of vitamin D insufficiency. Further 
research is required to directly compare young and old vitamin D 
sufficient individuals.  Hence, our findings will further add to the debate of 
vitamin D-VDR relationship in skeletal muscle and the ageing process.  
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For future research, robust screening of young participants will need to be 
performed due to the high prevalence of vitamin D deficiency. As VDR is 
central to mediating the genomic and non-genomic functions of vitamin 
D, establishing this relationship is paramount and represents the initial 
step in developing a better understanding of how we can best use vitamin 
D in improving skeletal muscle function. It is with this understanding that 
further research to translate laboratory findings into clinical research can 
be done, such as changes in VDR expression in human skeletal muscle in 
those treated with vitamin D supplementation and how it correlates with 
clinical outcomes.  
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APPENDIX  
Appendix 1 
Protein Isolation and Solubilisation Method from Trizol Prep 
After removing the clear supernatant that contains the RNA following the 
separation of RNA from DNA and proteins during extraction with Trizol: 
x Remove and discard the interphase (containing DNA) so that just 
the organic phase (lower pink phase that contains the proteins) 
remains. 
x Add 1.5ml Isopropanol per ml of Trizol originally used. 
x Mix, then leave at room temperature for at least 10 mins to allow 
protein to precipitate. 
x Spin tubes 12,000g for 10 mins. 
x Add 2ml wash solution (see below) and mix on daisy wheel for 20 
mins at room temperature. 
x Centrifuge at 7,500g for 5 mins at 4ͼ C. 
x Spin tubes at 12,000g for 10 mins and add 2ml wash. Mix on daisy 
wheel for 20 mins at room temperature. Do this twice (i.e. 3 washes 
in total) 
x After the final wash, vortex pellet in 2ml 100% EtOH (You can stop 
at this point, store your samples at -20ͼ C and complete the 
procedure later) and leave for 20 mins at room temperature. 
(Removes remaining phenol and dye) 
x Centrifuge at 7,500g for 5 mins at 4ͼ C 
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x Discard supernatant and resuspend pellet by adding 400µl Protein 
Resuspension Solution per sample (see below). 
x Sonicate on ice to redissolve. 
 
Wash Solution 
0.3M Guanidine HCl in 95% EtOH 
(mW=95.53) 
?1M = 95.54g in 1000ml 
?1M = 47.765g in 500ml 
?0.3M = 14.33g in 500ml of 95% EtOH  
Protein Resuspension Solution 
50mM Tris 
4% SDS 
9M Urea (deionised using Amberlite) 
For 100ml: 
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Tris   0.6055g (605mg) 
SDS   4g 
deionised Urea 54.05g 
1. Dissolve 54.05g Urea in 80ml HPLC water. 
2. Split into 2 x 50ml falcon tubes, add 2g Amberlite MB50/MB1 to each 
tube. 
3. Leave on roller for 1hr to deionise. 
4. Pool deionised urea and add Tris and SDS. 
5. Make up to 100ml with HPLC water. 
 
9M Urea     50mM Tris 
(mW=60.06)    (mW=121.1) 
?9M = 540.54g in 1000ml  ?1M = 121.1g in 1000ml 
?1M = 12.11g in 100ml 
?9M = 54.054g in 100ml ?50mM (0.05M) = 0.6055g in 
100ml 
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Appendix 2 
Real-time PCR analysis of RT products 
Procedure 
1. Take 20 µl of cDNA and add 140 µl of RNase free water (8-fold 
dilution). Vortex and spin (make a series of further 2-fold dilutions 
up to 128-fold and use them as a standard curve for every plate) 
2. Dilute prove and primers* 10-fold (ie take 30 µl of each primer and 
add 270 µl of RNAse free water). Vortex and spin 
3. Place 20 µl of Master (reaction) mix onto 96-well plate. 
4. Pipette 5 µl of each diluted cDNA in triplicate onto 96-well plate 
6.  Read on Taqman (~2 h each run) 
 
Reagents required 
2x Taqman Universal PCR Mastermix  
[(contains ampliTaq gold enzyme, nucleotides, internal reference dye ROX 
and buffer) from ABI Biosystems cat No.4304437 (store at 4oC)] 
 
Primers:  Forward and Reverse each at 10 pmol/µl (10µM)  
Keep master stocks at 100 pmol/µl (100µM) (store at -
20oC) 
 
Probe: GXDOODEHOOHGSUREHVWDQGDUGODEHOOLQJ¶)$0DQG¶7$05$ 
Working stock at 10 pmol/µl (10µM) (store at -20oC) 
Keep master stocks at 100 pmol/µl (100µM) 
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Template: First strand cDNA made from total RNA. 
 
Reactions must be done in tubes with optical clear lids.  The machine can 
take individual 0.2 ml tubes, strips or 96 well plates. 
 
Reaction set up 
Each reaction is in a final volume of 25µl (see below). 
 
               final concentration 
 
2x Taqman Universal PCR Mastermix 12.5µl      x1 
Forward primer (10 pmol/µl)   0.75µl  0.3µM 
Reverse primer (10 pmol/µl)   0.75µl  0.3µM 
Probe (dual labelled) (10 pmol/µl)  0.5µl   0.2µM 
cDNA (equivalent to 5ng total RNA/µl) 5µl      10ng RNA equiv. 
Water (molecular grade)   5.5µl   
Total volume     25 µl  
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